FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089236216> ?p ?o ?g. }

• W3089236216 endingPage "102107" @default.
• W3089236216 startingPage "102107" @default.
• W3089236216 abstract "Most women with advanced ovarian cancer respond to initial treatment, consisting of surgical resection and ≈6 cycles of platinum-based chemotherapy. However, disease recurrence occurs in most patients, and subsequent therapies become necessary. Historically, close monitoring following treatment (active surveillance) was the only available option, as continued maintenance chemotherapy treatment led to increased toxicity without providing any meaningful clinical benefit. Recently, targeted therapy with the angiogenesis inhibitor bevacizumab and the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib, niraparib, and rucaparib have demonstrated significant clinical benefits as maintenance treatment for recurrent disease. Despite consensus guidelines recommending their use, maintenance treatments are currently underutilized. Here, we review evidence from pivotal clinical trials of approved second-line maintenance treatments demonstrating efficacy in terms of progression-free survival and postprogression efficacy outcomes for patients with recurrent ovarian cancer. Adverse events frequently associated with bevacizumab include hypertension, proteinuria, and non-central nervous system bleeding, whereas PARP inhibitors are associated with nausea, vomiting, fatigue, and anemia. Patient-centered outcomes analyses show that PARP inhibitors provide significant benefits to patient health status, even when accounting for the toxicities associated with treatment. Many factors influence the selection of second-line maintenance treatment for patients with recurrent ovarian cancer, including the maintenance treatment received in the first-line setting. Overall, targeted maintenance treatment represents a new standard of care for patients with ovarian cancer, and we recommend that maintenance treatment should be offered to all eligible patients with recurrent ovarian cancer." @default.
• W3089236216 created "2020-10-01" @default.
• W3089236216 creator A5035470085 @default.
• W3089236216 creator A5047695952 @default.
• W3089236216 creator A5060787566 @default.
• W3089236216 creator A5073713547 @default.
• W3089236216 creator A5079485962 @default.
• W3089236216 creator A5083659627 @default.
• W3089236216 date "2020-11-01" @default.
• W3089236216 modified "2023-10-18" @default.
• W3089236216 title "Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment" @default.
• W3089236216 cites W1608269846 @default.
• W3089236216 cites W1793338775 @default.
• W3089236216 cites W1976817697 @default.
• W3089236216 cites W1981860337 @default.
• W3089236216 cites W1990474270 @default.
• W3089236216 cites W2000154336 @default.
• W3089236216 cites W2074453690 @default.
• W3089236216 cites W2081702389 @default.
• W3089236216 cites W2085215116 @default.
• W3089236216 cites W2113122060 @default.
• W3089236216 cites W2118548073 @default.
• W3089236216 cites W2127952549 @default.
• W3089236216 cites W2130078242 @default.
• W3089236216 cites W2135947389 @default.
• W3089236216 cites W2160466424 @default.
• W3089236216 cites W2171658624 @default.
• W3089236216 cites W2519148856 @default.
• W3089236216 cites W2528228811 @default.
• W3089236216 cites W2546059200 @default.
• W3089236216 cites W2550229146 @default.
• W3089236216 cites W2601370341 @default.
• W3089236216 cites W2605456582 @default.
• W3089236216 cites W2737389832 @default.
• W3089236216 cites W2744326576 @default.
• W3089236216 cites W2754327139 @default.
• W3089236216 cites W2760864027 @default.
• W3089236216 cites W2804717005 @default.
• W3089236216 cites W2806580171 @default.
• W3089236216 cites W2810447459 @default.
• W3089236216 cites W2883673963 @default.
• W3089236216 cites W2884001607 @default.
• W3089236216 cites W2891245632 @default.
• W3089236216 cites W2896628407 @default.
• W3089236216 cites W2906986535 @default.
• W3089236216 cites W2908639608 @default.
• W3089236216 cites W2925017121 @default.
• W3089236216 cites W2943935168 @default.
• W3089236216 cites W2946927158 @default.
• W3089236216 cites W2947176197 @default.
• W3089236216 cites W2951382000 @default.
• W3089236216 cites W2954523493 @default.
• W3089236216 cites W2972664697 @default.
• W3089236216 cites W2975141952 @default.
• W3089236216 cites W2976139792 @default.
• W3089236216 cites W2978650206 @default.
• W3089236216 cites W2979282490 @default.
• W3089236216 cites W2994977341 @default.
• W3089236216 cites W3012696018 @default.
• W3089236216 cites W3016364201 @default.
• W3089236216 cites W3020034962 @default.
• W3089236216 cites W3023274953 @default.
• W3089236216 cites W3023738757 @default.
• W3089236216 cites W3030531049 @default.
• W3089236216 cites W3030566019 @default.
• W3089236216 cites W3030838250 @default.
• W3089236216 cites W3031901775 @default.
• W3089236216 cites W3080218538 @default.
• W3089236216 doi "https://doi.org/10.1016/j.ctrv.2020.102107" @default.
• W3089236216 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33099187" @default.
• W3089236216 hasPublicationYear "2020" @default.
• W3089236216 type Work @default.
• W3089236216 sameAs 3089236216 @default.
• W3089236216 citedByCount "19" @default.
• W3089236216 countsByYear W30892362162020 @default.
• W3089236216 countsByYear W30892362162021 @default.
• W3089236216 countsByYear W30892362162022 @default.
• W3089236216 countsByYear W30892362162023 @default.
• W3089236216 crossrefType "journal-article" @default.
• W3089236216 hasAuthorship W3089236216A5035470085 @default.
• W3089236216 hasAuthorship W3089236216A5047695952 @default.
• W3089236216 hasAuthorship W3089236216A5060787566 @default.
• W3089236216 hasAuthorship W3089236216A5073713547 @default.
• W3089236216 hasAuthorship W3089236216A5079485962 @default.
• W3089236216 hasAuthorship W3089236216A5083659627 @default.
• W3089236216 hasBestOaLocation W30892362161 @default.
• W3089236216 hasConcept C104317684 @default.
• W3089236216 hasConcept C121608353 @default.
• W3089236216 hasConcept C126322002 @default.
• W3089236216 hasConcept C136948725 @default.
• W3089236216 hasConcept C141071460 @default.
• W3089236216 hasConcept C143998085 @default.
• W3089236216 hasConcept C177713679 @default.
• W3089236216 hasConcept C182979987 @default.
• W3089236216 hasConcept C185592680 @default.
• W3089236216 hasConcept C197934379 @default.
• W3089236216 hasConcept C2776694085 @default.
• W3089236216 hasConcept C2777802072 @default.

• next